Your partner for innovative medicines in emerging markets

In the recent months, we have strategically expanded our portfolio with several novel products, marking a significant step forward in our growth journey. This effort aligns with our overarching ambition to help more patients worldwide, particularly in underserved communities.

Our Commitment to Emerging Markets

At Acino, we are committed to providing novel healthcare solutions to physicians and patients, focusing on reducing the health burden in emerging markets. Our dedication lies in addressing unmet patient needs, ensuring that essential medicines become accessible to patients across the Middle East, Africa, Ukraine, the CIS region, and Latin America.

Strategic Partnerships for the Benefit of Patients

Allecra Therapeutics: We have partnered with Allecra Therapeutics to license and distribute EXBLIFEP® (cefepime/enmetazobactam) to combat high-risk infectious diseases in South Africa and the Gulf Cooperation Council (GCC) countries. This collaboration is crucial to providing patients with access to life-saving treatments.

Supernus Pharmaceuticals: In Latin America, our alliance with Supernus enhances our leadership postion in the central nervous system (CNS) therapeutic area. Together, we are introducing an innovative solution Qelbree® (viloxazine extended-release capsules) for treatment of a complex disease like attention deficit hyperactivity disorder (ADHD) in adults and children above 6 years old.

SERB Pharmaceuticals: Our partnership with SERB Pharmaceuticals in Latin America provides an important orphan drug Voraxaze® (glucarpidase) for cancer patients, addressing a critical need in onco-haematology care.

Sobi: In Kazakhstan, we have collaborated with Sobi to ensure access to essential therapies for patients with rare diseases such as rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial Mediterranean fever, Still’s disease, paroxysmal nocturnal haemoglobinuria, etc., furthering our mission to serve niche patient populations.

Bioprojet: Through our partnership with Bioprojet, we have acquired rights to commercialise pitolisant (a selective histamine H3-receptor antagonist/inverse agonist) to bring relief to patients, suffering from narcolepsy or obstructive sleeping apnoea (OSA) disorders, in Saudi Arabia, Kuwait, Oman, Qatar and UAE.

Why Partner with Acino?

Acino stands as the ideal partner for pharmaceutical companies of all sizes, from multinationals to small and medium-sized innovators. With our extensive expertise in high-growth markets and a robust sales network spanning over 60 countries, we empower our partners to amplify their market strategies and reach.

Our unwavering commitment to quality, innovation, and access to medicines is at the heart of every partnership. We adhere to the highest ethical standards and commercial integrity, ensuring that each collaboration is mutually beneficial and customer-centric.

Join us in our mission to improve people health. Together, we can make a significant impact on patients’ lives by delivering innovative and proven medicines to emerging markets.

Contact Us

We invite pharmaceutical companies to explore partnership opportunities with Acino. Let’s work together to bring healthcare solutions to the regions that need them most. Contact us today or meet us at CPHI to discuss how we can collaborate for the benefit of patients worldwide.